[1] Lin J,Wang Y C,Sun Z J,et al. 3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of
taxol resistant human ovarian cancer by inhibiting multidrug resistance(MDR) proteins function[J].
Biomed Pharmacother,2019,116:108992
[2] Yu C Y,Niu X L,Du Y R,et al. IL-17A promotes fatty acid uptake through the IL-17A/IL-17RA/p-
STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte-rich microenvironment[J]. Cancer Immunol
Immunother,2020,69(1):115
[3] Monteleone I,Pallone F,Monteleone G. Th17-related cytokines: new players in the control of
chronic intestinal inflammation[J]. BMC Med,2011,9:122
[4] Xing X, Yang J,Yang X, et al. IL-17A induces endothelial inflammation in systemic sclerosis
via the ERK signaling pathway[J]. PLoS One,2013,8(12):e85032
[5] Numasaki M, Tsukamoto H, Tomioka Y, et al. A heterodimeric cytokine,consisting of IL-17A and
IL-17F,promotes migration and capillary-like tube formation of human vascular endothelial cells[J].
Tohoku J Exp Med,2016,240(1):47
[6] Li S S, Li C K, Tang M Y, et al. Modeling ovarian cancer multicellular spheroid behavior in a
dynamic 3D peritoneal microdevice[J]. J Vis Exp,2017,(120):27
[7] Chen Z J, Zhang Z, Xie B B, et al.Clinical significance of up-regulated lncRNA NEAT1 in
prognosis of ovarian cancer[J]. Eur Rev Med Pharmacol Sci,2016,20(16):3373
[8] Beltran E G,Denisenko T V,Zhivotovsky B,et al. Tudor staphylococcal nuclease: biochemistry
and functions[J]. Cell Death Differ,2016,23(11):1739
[9] Liang H,Yu T,Han Y,et al. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian
cancer by competitively binding miR-101-3p to regulate ZEB1 expression[J]. Mol Cancer,2018,17(1):
119
[10] Azais H,Mordon S, Collinet P. Intraperitoneal photodynamic therapy for peritoneal metastasis of
epithelial ovarian cancer. Limits and future prospects[J]. Gynecol Obstet Fertil Senol,2017,45(4):
249
[11] Ladanyi A,Mukherjee A,Kenny H A,et al. Adipocyte-induced CD36 expression drives ovarian cancer
progression and metastasis[J]. Oncogene,2018,37(17):2285
[12] Nakamura K,Sawada K,Kinose Y,et al. Exosomes promote ovarian cancer cell invasion through
transfer of CD44 to peritoneal mesothelial cells[J]. Mol Cancer Res,2017,15(1):78
[13] Sugauchi F,Orito E,Kato H,The complete nucleotide sequences of serotype ′O′ and ′A′ Indian
vaccine strains of foot-and-mouth disease virus[J]. Arch Virol,2011,156(11):2117
[14] Jayakumar A,Bothwell ALM. Functional diversity of myeloid-derived suppressor cells:the
multitasking hydra of cancer[J]. J Immunol,2019,203(5):1095
[15] Chen Y,Zhong M,Yuan G,et al. Interleukin-17 induces angiogenesis in vitro via CXCL8 and CCL2 in
retinal pigment epithelium[J]. Mol Med Rep,2018,17(3):4627
[16] Ohman A W,Hasan N,Dinulescu D M. Advances in tumor screening,imaging,and avatar technologies
for high-grade serous ovarian cancer[J]. Front Oncol,2014,4:322
[17] Worzfeld T,Pogge E,Huber M,et al. The unique molecular and cellular microenvironment of ovarian
cancer[J]. Front Oncol,2017,7:24
[18] Nieman K M,Kenny H A,Penicka C V,et al. Adipocytes promote ovarian cancer metastasis and
provide energy for rapid tumor growth[J]. Nat Med,2011,17(11):1498
[1]申彦,张新莹,师宜荃,等.Glut-1、HIF-1α及P53在卵巢癌中的表达及意义[J].天津医科大学学报,2013,19(05):383.
[2]周 闻,杨 臻,刘 民,等.抑癌基因ST7L对卵巢癌细胞增殖、细胞周期和裸鼠移植瘤的影响[J].天津医科大学学报,2016,22(05):373.
ZHOU Wen,YANG Zhen,LIU Min,et al.Effects of ST7L on cell proliferation, cell cycle in ovarian cancer and tumour xenografts in nude mice[J].Journal of Tianjin Medical University,2016,22(06):373.
[3]范 丹,宋文静,张艳辉,等.PRRX1的表达对卵巢癌血管生成拟态形成及患者预后的影响[J].天津医科大学学报,2018,24(01):1.
FAN Dan,SONG Wen-jing,ZHANG Yan-hui,et al.Effect of PRRX1 expression on VM formation and prognosis in ovarian cancer[J].Journal of Tianjin Medical University,2018,24(06):1.
[4]王雅蕾,王靖怡 综述,齐丽莎 审校.微环境在卵巢癌发生发展中的作用[J].天津医科大学学报,2020,26(03):288.
[5]李广宁 综述,曹文枫 审校.女性生殖系统双原发癌的研究进展[J].天津医科大学学报,2021,27(06):655.
[6]沈洋洋,牛秀珑,郁春艳,等.外源性IL-6 通过STAT3 通路促进卵巢癌细胞对顺铂
耐药[J].天津医科大学学报,2022,28(03):266.
SHEN Yang-yang,NIU Xiu-long,YU Chun-yan,et al.Exogenous IL-6 promotes cisplatin resistance of ovarian cancer through STAT3 pathway[J].Journal of Tianjin Medical University,2022,28(06):266.
[7]徐灵灵,牛秀珑,张宏健,等.IL-17A促进卵巢癌顺铂耐药的体外机制探讨[J].天津医科大学学报,2018,24(03):192.
XU Ling-ling,NIU Xiu-long,ZHANG Hong-jian,et al.Study on the underlying mechanisms of IL-17A promoting the cisplatin-based resistance of ovarian cancer[J].Journal of Tianjin Medical University,2018,24(06):192.
[8]郑小燕,郁春艳,刘俊汝,等.IL-17A对卵巢癌进展的影响及机制研究[J].天津医科大学学报,2023,29(02):148.
ZHENG Xiao-yan,YU Chun-yan,LIU Jun-ru,et al.Effect and mechanism of IL-17A on the progression of ovarian cancer[J].Journal of Tianjin Medical University,2023,29(06):148.